{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:52:59Z","timestamp":1780411979191,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012352","name":"Universit\u00e0 degli Studi di Milano","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiol med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>Evaluating the pathological response and the survival outcomes of combined thermal ablation (TA) and transarterial chemoembolization (TACE) as a bridge or downstaging for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) &gt;\u00a03\u00a0cm.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>A retrospective review encompassed 36 consecutive patients who underwent combined TA-TACE as bridging or downstaging before LT. Primary objectives included necrosis of the target lesion at explant pathology, post-LT overall survival (OS) and post-LT recurrence-free survival (RFS). For OS and RFS, a comparison with 170 patients subjected to TA alone for nodules &lt;3\u00a0cm in size was also made.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Out of the 36 patients, 63.9% underwent TA-TACE as bridging, while 36.1% required downstaging. The average node size was 4.25\u00a0cm. All cases were discussed in a multidisciplinary tumor board to assess the best treatment for each patient. Half received radiofrequency (RF), and the other half underwent microwave (MW). All nodes underwent drug-eluting beads (DEB) TACE with epirubicin. The mean necrosis percentage was 65.9% in the RF+TACE group and 83.3% in the MW+TACE group (<jats:italic>p<\/jats:italic>-value\u00a0=\u00a00.099). OS was 100% at 1 year, 100% at 3 years and 94.7% at 5 years. RFS was 97.2% at 1 year, 94.4% at 3 years and 90% at 5 years. Despite the different sizes of the lesions, OS and RFS did not show significant differences with the cohort of patients subjected to TA alone.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The study highlights the effectiveness of combined TA-TACE for HCC&gt;3 cm, particularly for bridging and downstaging to LT, achieving OS and RFS rates significantly exceeding 80% at 1, 3 and 5 years.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11547-024-01830-x","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T06:02:28Z","timestamp":1717394548000},"page":"1086-1097","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Combined transarterial chemoembolization and thermal ablation in candidates to liver transplantation with hepatocellular carcinoma: pathological findings and post-transplant outcome"],"prefix":"10.1007","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1227-9040","authenticated-orcid":false,"given":"Marco","family":"Fronda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9554-9085","authenticated-orcid":false,"given":"Eleonora","family":"Susanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doriguzzi Breatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Gazzera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Patrono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Piccione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bertero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Ciferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Carucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Gaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Rolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Vocino Trucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bergamasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Tandoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cassoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Romagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Fonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0297-0700","authenticated-orcid":false,"given":"Marco","family":"Calandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"key":"1830_CR1","unstructured":"Istituto Superiore di Sanit\u00e0 (2022) I numeri del cancro in Italia"},{"key":"1830_CR2","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/hep.31187","volume":"72","author":"A Vitale","year":"2020","unstructured":"Vitale A, Trevisani F, Farinati F, Cillo U (2020) Treatment of hepatocellular carcinoma in the precision medicine era: from treatment stage migration to therapeutic hierarchy. Hepatol Baltim Md 72:2206\u20132218","journal-title":"Hepatol Baltim Md"},{"key":"1830_CR3","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.1016\/S1470-2045(23)00186-9","volume":"24","author":"A Vitale","year":"2023","unstructured":"Vitale A et al (2023) Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept. Lancet Oncol 24:e312\u2013e322","journal-title":"Lancet Oncol"},{"key":"1830_CR4","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1053\/j.gastro.2017.09.025","volume":"154","author":"V Mazzaferro","year":"2018","unstructured":"Mazzaferro V et al (2018) Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology 154:128\u2013139","journal-title":"Gastroenterology"},{"key":"1830_CR5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1001\/jamasurg.2021.0954","volume":"156","author":"KJ Halazun","year":"2021","unstructured":"Halazun KJ et al (2021) Dynamic \u03b1-fetoprotein response and outcomes after liver transplant for hepatocellular carcinoma. JAMA Surg 156:559\u2013567","journal-title":"JAMA Surg"},{"key":"1830_CR6","doi-asserted-by":"publisher","first-page":"5558","DOI":"10.3390\/cancers13215558","volume":"13","author":"L Crocetti","year":"2021","unstructured":"Crocetti L et al (2021) Locoregional treatments for bridging and downstaging HCC to liver transplantation. Cancers 13:5558","journal-title":"Cancers"},{"key":"1830_CR7","first-page":"779","volume":"157","author":"P Tabrizian","year":"2022","unstructured":"Tabrizian P et al (2022) Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma. JAMA Surg 157:779\u2013788","journal-title":"JAMA Surg"},{"key":"1830_CR8","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3390\/cancers12020452","volume":"12","author":"Q Lai","year":"2020","unstructured":"Lai Q et al (2020) Identification of an upper limit of tumor burden for downstaging in candidates with hepatocellular cancer waiting for liver transplantation: a west-east collaborative effort. Cancers 12:452","journal-title":"Cancers"},{"key":"1830_CR9","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S1470-2045(20)30224-2","volume":"21","author":"V Mazzaferro","year":"2020","unstructured":"Mazzaferro V et al (2020) Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b\/3 trial. Lancet Oncol 21:947\u2013956","journal-title":"Lancet Oncol"},{"key":"1830_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/cncr.20798","volume":"103","author":"A Sasaki","year":"2005","unstructured":"Sasaki A et al (2005) Microsatellite distribution and indication for locoregional therapy in small hepatocellular carcinoma. Cancer 103:299\u2013306","journal-title":"Cancer"},{"key":"1830_CR11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s11605-019-04503-7","volume":"25","author":"S Famularo","year":"2021","unstructured":"Famularo S et al (2021) Factors affecting local and intra hepatic distant recurrence after surgery for Hcc: an alternative perspective on microvascular invasion and satellitosis - a Western European multicentre study. J Gastrointest Surg Off J Soc Surg Aliment Tract 25:104\u2013111","journal-title":"J Gastrointest Surg Off J Soc Surg Aliment Tract"},{"key":"1830_CR12","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.1002\/cncr.25314","volume":"116","author":"M Morimoto","year":"2010","unstructured":"Morimoto M et al (2010) Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 116:5452\u20135460","journal-title":"Cancer"},{"key":"1830_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3348\/kjr.2016.17.1.93","volume":"17","author":"X Wang","year":"2016","unstructured":"Wang X et al (2016) Efficacy and safety of radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinomas compared with radiofrequency ablation alone: a time-to-event meta-analysis. Korean J Radiol 17:93\u2013102","journal-title":"Korean J Radiol"},{"key":"1830_CR14","doi-asserted-by":"publisher","first-page":"052","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet J (2010) Modified recist (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:052\u2013060","journal-title":"Semin Liver Dis"},{"key":"1830_CR15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1053\/jhep.2001.22172","volume":"33","author":"PS Kamath","year":"2001","unstructured":"Kamath PS et al (2001) A model to predict survival in patients with end-stage liver disease. Hepatol Baltim Md 33:464\u2013470","journal-title":"Hepatol Baltim Md"},{"key":"1830_CR16","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson PJ et al (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol Off J Am Soc Clin Oncol 33:550\u2013558","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1830_CR17","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1001\/jamaoncol.2016.5116","volume":"3","author":"N Mehta","year":"2017","unstructured":"Mehta N et al (2017) Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol 3:493\u2013500","journal-title":"JAMA Oncol"},{"key":"1830_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12957-021-02188-4","volume":"19","author":"C Jiang","year":"2021","unstructured":"Jiang C, Cheng G, Liao M, Huang J (2021) Individual or combined transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma: a time-to-event meta-analysis. World J Surg Oncol 19:81","journal-title":"World J Surg Oncol"},{"key":"1830_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1399-0012.2004.00164.x","volume":"18","author":"LL Wong","year":"2004","unstructured":"Wong LL, Tanaka K, Lau L, Komura S (2004) Pre-transplant treatment of hepatocellular carcinoma: assessment of tumor necrosis in explanted livers. Clin Transplant 18:227\u2013234","journal-title":"Clin Transplant"},{"key":"1830_CR20","doi-asserted-by":"publisher","first-page":"225","DOI":"10.21037\/hbsn.2016.01.05","volume":"5","author":"R Vasnani","year":"2016","unstructured":"Vasnani R et al (2016) Radiofrequency and microwave ablation in combination with transarterial chemoembolization induce equivalent histopathologic coagulation necrosis in hepatocellular carcinoma patients bridged to liver transplantation. Hepatobiliary Surg Nutr 5:225\u2013233","journal-title":"Hepatobiliary Surg Nutr"},{"key":"1830_CR21","first-page":"160","volume":"12","author":"L Centonze","year":"2022","unstructured":"Centonze L et al (2022) From LI-RADS classification to hcc pathology: a retrospective single-institution analysis of clinico-pathological features affecting oncological outcomes after curative surgery. Diagn Basel Switz 12:160","journal-title":"Diagn Basel Switz"},{"key":"1830_CR22","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/jgh.13632","volume":"32","author":"EC Lee","year":"2017","unstructured":"Lee EC et al (2017) Survival analysis after liver resection for hepatocellular carcinoma: a consecutive cohort of 1002 patients. J Gastroenterol Hepatol 32:1055\u20131063","journal-title":"J Gastroenterol Hepatol"},{"key":"1830_CR23","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jhep.2020.03.018","volume":"73","author":"A Cucchetti","year":"2020","unstructured":"Cucchetti A et al (2020) Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant. J Hepatol 73:342\u2013348","journal-title":"J Hepatol"},{"key":"1830_CR24","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1016\/j.ejrad.2012.12.009","volume":"82","author":"I Bargellini","year":"2013","unstructured":"Bargellini I et al (2013) Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. Eur J Radiol 82:e212-218","journal-title":"Eur J Radiol"},{"key":"1830_CR25","first-page":"228","volume":"25","author":"DD Lee","year":"2019","unstructured":"Lee DD et al (2019) The mRECIST classification provides insight into tumor biology for patients with hepatocellular carcinoma awaiting liver transplantation. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc 25:228\u2013241","journal-title":"Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc"},{"key":"1830_CR26","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1097\/MEG.0000000000000688","volume":"28","author":"E Sheta","year":"2016","unstructured":"Sheta E et al (2016) Comparison of single-session transarterial chemoembolization combined with microwave ablation or radiofrequency ablation in the treatment of hepatocellular carcinoma: a randomized-controlled study. Eur J Gastroenterol Hepatol 28:1198\u20131203","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1830_CR27","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/jgh.12088","volume":"28","author":"L-F Xu","year":"2013","unstructured":"Xu L-F et al (2013) Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. J Gastroenterol Hepatol 28:456\u2013463","journal-title":"J Gastroenterol Hepatol"},{"key":"1830_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1148\/radiology.217.1.r00se02119","volume":"217","author":"S Rossi","year":"2000","unstructured":"Rossi S et al (2000) Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 217:119\u2013126","journal-title":"Radiology"},{"issue":"Suppl 8","key":"1830_CR29","first-page":"P34","volume":"14","author":"L Solbiati","year":"2004","unstructured":"Solbiati L, Tonolini M, Cova L (2004) Monitoring RF ablation. Eur Radiol 14(Suppl 8):P34-42","journal-title":"Eur Radiol"},{"key":"1830_CR30","first-page":"471","volume":"26","author":"H-C Liu","year":"2014","unstructured":"Liu H-C et al (2014) Combination of percutaneous radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: observation of clinical effects. Chin J Cancer Res Chung-Kuo Yen Cheng Yen Chiu 26:471\u2013477","journal-title":"Chin J Cancer Res Chung-Kuo Yen Cheng Yen Chiu"},{"key":"1830_CR31","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1097\/01.tp.0000209641.88912.15","volume":"81","author":"A Grasso","year":"2006","unstructured":"Grasso A et al (2006) Liver transplantation and recurrent hepatocellular carcinoma: predictive value of nodule size in a retrospective and explant study. Transplantation 81:1532\u20131541","journal-title":"Transplantation"},{"key":"1830_CR32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/hepr.12568","volume":"46","author":"Y Wang","year":"2016","unstructured":"Wang Y, Deng T, Zeng L, Chen W (2016) Efficacy and safety of radiofrequency ablation and transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a meta-analysis. Hepatol Res Off J Jpn Soc Hepatol 46:58\u201371","journal-title":"Hepatol Res Off J Jpn Soc Hepatol"},{"key":"1830_CR33","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/MEG.0b013e32835a0a07","volume":"25","author":"Z Lu","year":"2013","unstructured":"Lu Z et al (2013) Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol 25:187\u2013194","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["La radiologia medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-024-01830-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11547-024-01830-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-024-01830-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T11:31:20Z","timestamp":1721129480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11547-024-01830-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["1830"],"URL":"https:\/\/doi.org\/10.1007\/s11547-024-01830-x","relation":{},"ISSN":["1826-6983"],"issn-type":[{"value":"1826-6983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]},"assertion":[{"value":"11 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MC acted as a consultant for: Medtronic. The other authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study adhered to the principles of the Declarations of Helsinki and Istanbul. Written consent for TA-TACE procedures and the use of medical records was obtained from all patients. Due to the retrospective observational nature of this research, and in accordance with Italian law, no formal ethical approval from the local Institutional Review Board\/Independent Ethics Committee was needed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}